中危重度主动脉瓣狭窄患者经导管与外科主动脉瓣置换的成本效益
基于PARTNER 2试验(2A随机队列及S3i注册队列)的中危重度主动脉瓣狭窄患者数据,结合试验内成本、EQ-5D效用值与生存数据构建Markov模型,从美国医疗体系角度评估TAVR相比SAVR的终身成本效益。
要点
- 中危AS患者中,TAVR相比SAVR终身成本更低且质量调整生存更优。
- SAPIEN 3瓣膜TAVR经济占优概率达97%,SAPIEN XT瓣膜为84%。
- 若长期死亡率相当,TAVR可能成为中危AS患者的优选策略。
核心结论
- 在中危重度主动脉瓣狭窄患者中,从美国医疗体系角度看,TAVR相比SAVR在经济上占优,提供更高的质量调整预期寿命和更低的长期成本。
研究设计与样本
- 基于PARTNER 2试验(2011–2014年,共3110例中危AS患者),其中2032例随机分配至XT-TAVR或SAVR(PARTNER 2A),1078例进入S3-TAVR注册队列。
- 使用试验内成本、EQ-5D效用值和生存数据构建Markov模型,从美国医疗体系角度估算终身成本效益。
主要发现
- XT-TAVR和S3-TAVR相比SAVR在经济上占优的bootstrap重复比例分别为84%和97%。
临床怎么用
- 对于中危重度AS患者,TAVR不仅临床结局与SAVR相似,且长期经济性更优,可作为治疗决策的重要参考。
- SAPIEN 3瓣膜相比SAPIEN XT瓣膜显示出更高的经济占优概率,选择时需结合瓣膜类型。
局限性
- 长期数据(如晚期死亡率)尚未完全证实TAVR与SAVR相当,结论基于模型外推。
- 成本估算部分依赖Medicare索赔数据链接或线性回归模型填补,可能存在不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with severe aortic stenosis (AS) at intermediate surgical risk, treatment with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) results in similar rates of death or stroke at 2 years. Whether TAVR is cost-effective compared with SAVR for intermediate-risk patients remains uncertain. METHODS: Between 2011 and 2014, 3110 intermediate-risk AS patients were treated with TAVR or SAVR in the PARTNER 2 trial (Placement of Aortic Transcatheter Valves 2). A total of 2032 patients were randomized to receive TAVR using the SAPIEN XT valve (XT-TAVR) or SAVR in the PARTNER 2A trial, whereas the PARTNER S3i registry included an additional 1078 patients treated with TAVR using the SAPIEN 3 valve (S3-TAVR), which offers a lower delivery profile and sealing skirt designed to reduce paravalvular regurgitation compared with XT-TAVR. Procedural costs were estimated using measured resource utilization. Other in-trial costs were assessed by linkage of trial data with Medicare claims (n=2333) or by linear regression models for unlinked patients (n=682). Health utilities were estimated using the EQ-5D at baseline and 1, 12, and 24 months. Using a Markov model informed by in-trial costs, utilities, and survival data, lifetime cost-effectiveness from the perspective of the US healthcare system was estimated in terms of cost per quality-adjusted life-year gained. RESULTS: Although procedural costs were ≈$20 000 higher with TAVR than SAVR, total cost differences for the index hospitalization were only $2888 higher with XT-TAVR ( P=0.014) and were $4155 lower with S3-TAVR ( P<0.001) owing to reductions in length of stay with TAVR. Follow-up costs were significantly lower with XT-TAVR (Δ=-$9304; P<0.001) and S3-TAVR (Δ=-$11 377; P<0.001) than with SAVR. Over a lifetime horizon, TAVR was projected to lower total costs by $8000 to $10 000 and to increase quality-adjusted survival by 0.15 to 0.27 years. XT-TAVR and S3-TAVR were found to be economically dominant compared with SAVR in 84% and 97% of bootstrap replicates, respectively. CONCLUSIONS: Among intermediate-risk AS patients, TAVR is projected to be economically dominant from the perspective of the US healthcare system by providing both greater quality-adjusted life expectancy and lower long-term costs than SAVR. If long-term data demonstrate comparable late mortality with TAVR and SAVR, these findings suggest that TAVR might be the preferred treatment strategy for intermediate-risk AS patients based on both clinical and economic considerations. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01314313.
引用
- Baron SJ, Wang K, House JA, et al. Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk. Circulation. 2019. PMID: 30586747. doi:10.1161/CIRCULATIONAHA.118.035236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。